Repros Thera leaps as Androxal meets study endpoints

USA-based Repros Therapeutics (Nasdaq: RPRX) saw its shares rocket more than 74% to $15.90 by early afternoon trading (March 28), after the company reported positive top-line results for the first pivotal study of Androxal, ZA-301, in the treatment of secondary hypogonadism.

Results for the Intent-to-Treat population met both co-primary endpoints mandated by the Food and Drug Administration on namely testosterone and sperm levels. The Intent-to-Treat population included all men randomized in the study whether or not they completed the study. 151 subjects were randomized into the study, 38 on placebo and 113 on Androxal.

Assuming that the drug is approved, it would join a market sector that already includes is AbbVie’s Androgel (testosterone gel), Auxilium Pharmaceuticals’ Testim (testosterone gel), and Eli Lilly’s Axiron (testosterone topical solution).